---
title: "VK2735 in Chronic weight management: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on VK2735 in Chronic weight management: Co-prescribed/Concomitant therapies. Topics: Subcutaneous formulation: reduced-calorie diet and exercise counseling in the phase 2 trial, Subcutaneous formulation: reduced-calorie diet and exercise counseling in the VANQUISH phase 3 trials, Oral formulation: exercise and caloric intake advice in the phase 2 trial, Subcutaneous formulation: background glucose-lowering therapy permitted in VANQUISH-2, and 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Subcutaneous formulation: reduced-calorie diet and exercise counseling in the phase 2 trial

> “All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal. Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.12-2"></a>

### Subcutaneous formulation: reduced-calorie diet and exercise counseling in the VANQUISH phase 3 trials

> “All groups: Counseling for reduced calorie diet and exercise”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf); [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-2.1.2.12-3"></a>

### Oral formulation: exercise and caloric intake advice in the phase 2 trial

> “All groups: Advised to exercise and reduce caloric intake”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-2.1.2.12-4"></a>

### Subcutaneous formulation: background glucose-lowering therapy permitted in VANQUISH-2

> “Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-2.1.2.12-5"></a>

### Oral formulation: background glucose-lowering therapy permitted in SUNRISE-2

> “Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-2.1.2.12-6"></a>

### Subcutaneous formulation: glucose-lowering agents excluded in VANQUISH-1

> “Treatment with glucose-lowering agent(s) within 90 days before screening”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-2.1.2.12-7"></a>

### Subcutaneous formulation: prior incretin and weight-loss medications excluded

> “Use of any GLP-1 RA or dual GLP-1/GIP receptor agonist or analogs within 6 months of screening”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-2.1.2.12-8"></a>

### Oral formulation: prior incretin and weight-loss medications excluded

> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-2.1.2.12-9"></a>

### Subcutaneous formulation: prior or planned metabolic and bariatric surgery or endoscopic therapy excluded in VANQUISH-1

> “Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)”
> “Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
